LRP1B is considered a tumor suppressor and its somatic mutability was recently associated with improved OS of CRC patients [27], higher tumor mutation burden and tumor neoantigen burden connected with benefit from PD-1 blockade in MMR-proficient rectal carcinomas [28]. Here, LRP1B is linked to rectal carcinoma.